HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E2970 Gramicidin Gramicidin from Bacillus aneurinolyticus (Bacillus brevis) is an antimicrobial peptide that destroys gram-positive bacteria. It inhibits the growth of bacteria by forming pores and channels in the cell wall, which increase its permeability to monovalent cations. Jul 06 2023
E2980 4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 4-AMino-1-phenylpyrazole[3,4-d]pyriMidine(PP 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM. It is a negative control for the Src kinase inhibitor, PP 2. Jul 05 2023
E2965 4-Nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside 4-Nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside is a useful substrate for rapid colorimetric assay of N-acetyl-b-glucosaminidase activity in human urine. Chromogenic β-Glucosaminidase substrate yielding a yellow solution upon cleavage, employed particularly in yeasts and molds. Jul 05 2023
E2994 Sodium hydroxide Sodium hydroxide (NaOH) is a caustic reagent that is widely used to neutralize acids and prepare sodium salts of reagents. It is used in various industries, including textiles, drinking water, soaps and detergents, pulp and paper manufacturing, and as a drain cleaner.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing. Jul 05 2023
E1267 MDL-800 MDL 800 is an allosteric activator of sirtuin 6 (SIRT6). It selectively activates SIRT6 deacetylase activity over SIRT1-5 and -7 and histone deacetylase 1 (HDAC1) and HDAC2-11 deacetylase activity in cell-free assays at 100 µM. It induces histone deacetylation, and reduces proliferation of BEL-7405 hepatocellular carcinoma (HCC) cells with EC50 of 90.4 µM. Jul 03 2023
E2957 N-Dodecyl beta-D-maltoside N-Dodecyl-β-D-maltoside (Lauryl Maltoside) is a derivatives of pyrene (Py). It is alkyl maltopyranoside detergent, especially in transporters and respiratory complexes. N-Dodecyl-β-D-maltoside has also been employed in applications such as in the purification and stabilization of RNA polymerase and detection of protein-lipid interactions. Jul 03 2023
E2993 Ruthenium Red Ruthenium red (Ammoniated ruthenium oxychloride) is a polycationic dye, which is a L-type calcium current (ICa) blocker. It is widely used for electron microscopy (EM) of cells, tissues and vegetative bacteria. Ruthenium red strongly reacts with phospholipids and fatty acids and binds to acidic mucopolysaccharides. Jul 03 2023
E1376 MitoSOX Red MitoSOX Red is a modified dihydroethidium (DHE) analog derived by the addition of a triphenylphosphonium group. It is a fluorescent probe used for imaging superoxide in the mitochondria of living cells. Jul 02 2023
E2971 Influenza Hemagglutinin (HA) Peptide Influenza Hemagglutinin (HA) Peptide is a synthetic peptide with an amino acid sequence of N-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-C. It is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry. It is used for competing out the anti-HA antibody binding to HA-tagged fusion proteins in immunoassays. It may also be used to to elute HA-tagged fusion proteins from an affinity column of Monoclonal Anti-HA agarose. Jul 02 2023
E2991 Gold(III) chloride trihydrate Gold(III) chloride trihydrate is a reducing agent. Gold(III) chloride trihydrate can be used for the chemical synthesis of gold nanoparticles (NP). Jul 02 2023
E2992 Oleoyl-L-alpha-lysophosphatidic acid sodium salt Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors. Jul 02 2023
D4045 Brentuximab vedotin Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. Jun 30 2023
D4046 Telisotuzumab vedotin Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours. Jun 30 2023
D4048 Labetuzumab govitecan Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer. Jun 30 2023
D4049 Disitamab vedotin Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer. Jun 30 2023
D4050 Datopotamab deruxtecan Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC. Jun 30 2023
D4051 Tisotumab vedotin Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. Jun 30 2023
D4052 Trastuzumab MMAE Trastuzumab MMAE is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody, conjugated to Monomethyl Auristatin E (MMAE), via a Mc linker. Trastuzumab MMAE has the potential for use in research of solid tumors mainly in HER2-positive breast cancer. Jun 30 2023
D4053 Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma. Jun 30 2023
D4054 Glembatumumab vedotin Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma. Jun 30 2023